CHMMF (Chimeric Therapeutics) YoY EBITDA Growth: -41.77% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHMMF Chimeric Therapeutics Ltd CHMMF
13 GF Score
Price $0.10
! 1 Warning Sign
View Full Analysis

What is Chimeric Therapeutics YoY EBITDA Growth?

Chimeric Therapeutics CHMMF -96.67% 13 YoY EBITDA Growth is -41.77% as of Dec. 2025. GuruFocus rates CHMMF with a GF Score™ of 13/100. The stock has 1 warning sign investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Chimeric Therapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2025 was -41.77%.

Chimeric Therapeutics's EBITDA per Share for the six months ended in Dec. 2025 was $-0.22.

Chimeric Therapeutics YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Chimeric Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chimeric Therapeutics YoY EBITDA Growth Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
YoY EBITDA Growth
0.00 56.50 -45.93 70.88 57.03

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only 117.66 40.27 -151.13 73.89 -41.77
CHMMF
13GF Score
Chimeric Therapeutics Ltd CHMMF
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chimeric Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Chimeric Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Jun. 2025 is calculated as:

YoY EBITDA Growth (A: Jun. 2025 )
=(EBITDA per Share (A: Jun. 2025 )-EBITDA per Share (A: Jun. 2024 ))/ | EBITDA per Share (A: Jun. 2024 ) |
=(-0.437--1.017)/ | -1.017 |
=57.03 %

Chimeric Therapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (Q: Dec. 2025 )
=(EBITDA per Share (Q: Dec. 2025 )-EBITDA per Share (Q: Dec. 2024 )) / | EBITDA per Share (Q: Dec. 2024 )) |
=(-0.224--0.158)/ | -0.158 |
=-41.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -41.77% mean?
Chimeric Therapeutics (CHMMF) has a YoY EBITDA Growth of -41.77% as of Dec. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Chimeric Therapeutics and its competitors.
Is Chimeric Therapeutics' YoY EBITDA Growth too high?
Chimeric Therapeutics' current YoY EBITDA Growth is -41.77%. Overall, Chimeric Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Chimeric Therapeutics' YoY EBITDA Growth compare to VRTX and REGN?
Chimeric Therapeutics' YoY EBITDA Growth of -41.77% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Chimeric Therapeutics and its competitors. Chimeric Therapeutics's current YoY EBITDA Growth is -41.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chimeric Therapeutics stock overvalued right now?
Chimeric Therapeutics (CHMMF) has a current YoY EBITDA Growth of -41.77%. The current YoY EBITDA Growth is -41.77%. Chimeric Therapeutics' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Chimeric Therapeutics (CHMMF), the current YoY EBITDA Growth is -41.77% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chimeric Therapeutics Business Description

Other Exchanges CHM:Australia
Address 62 Lygon Street, Level 3, Carlton, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.
13GF Score

Get the complete analysis for CHMMF

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.10
Price